[{"orgOrder":0,"company":"Amgen Inc","sponsor":"NewAmsterdam Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Obicetrapib","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ NewAmsterdam Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.20000000000000001,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Morningside Ventures","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Morningside Ventures"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Lifesciences Acquisition Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Merger","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Lifesciences Acquisition Corporation","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Frazier Lifesciences Acquisition Corporation"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.23999999999999999,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Genetic Disease","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Lifesciences Acquisition Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Genetic Disease","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Lifesciences Acquisition Corporation","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Frazier Lifesciences Acquisition Corporation"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Private Placement","leadProduct":"Obicetrapib","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.23999999999999999,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":1.0600000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.0600000000000001,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Menarini"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Obicetrapib","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Jefferies"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Menarini","sponsor":"NewAmsterdam Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Menarini \/ NewAmsterdam Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Menarini \/ NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NewAmsterdam Pharma \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Obicetrapib
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
